IMVARIA
About IMVARIA
IMVARIA is a leading healthcare technology company pioneering work with AI biomarkers to redefine how to approach complex diseases more effectively. We bring artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases.
Company Mission and Products
IMVARIA is a software-as-medical-device (SaMD) company pioneering AI-driven digital biomarker solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease and reduce the need for invasive biopsy testing. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its Digital Biomarker Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA's FDA-authorized products include Fibresolve, the first AI diagnostic tool for lung fibrosis including idiopathic pulmonary fibrosis (IPF), and ScreenDx, an AI-powered screening algorithm for interstitial lung disease (ILD). The company aims to improve patient outcomes through novel AI biomarkers and collaboration with research institutions such as Mayo Clinic.
Location and Contact
Based in Berkeley, California, IMVARIA is a remote-first company embracing flexible work schedules. The company can be contacted via email at [email protected] and phone at (650) 683-9800. Their LinkedIn page provides more information and updates about the company.